(UroToday.com) The 2025 ASTRO annual meeting featured a biomarker breakthroughs prostate cancer session and a discussant presentation by Dr. Alan Dal Pra. Dr. Dal Pra noted that amongst the six ...

In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery ...

The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...

(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...

No patients died of prostate cancer. The 5-year overall survival was 90%.

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a ...